Moody’s downgrades Senegal to Caa1 amid rising debt concerns
William Andrew Macan, the Executive Vice President, General Counsel, Chief Compliance Officer, and Corporate Secretary of Neuronetics , Inc. (NASDAQ:STIM), recently executed a stock transaction involving the sale of company shares. According to a recent filing, Macan sold 1,970 shares of Neuronetics’ common stock. The shares were sold at a weighted average price of $3.28 per share, amounting to a total transaction value of $6,461. The stock, which currently trades at $3.97, has shown remarkable momentum with a 427% return over the past six months, according to InvestingPro data.
The transaction was conducted on February 10, 2025, and was a non-discretionary sale to cover tax obligations related to the vesting of a restricted stock unit award. Following this sale, Macan continues to hold 400,822 shares of Neuronetics. Based on InvestingPro analysis, the company maintains strong liquidity with a current ratio of 3.16, though its RSI suggests the stock is currently in overbought territory. Investors can access 10+ additional exclusive ProTips and comprehensive financial metrics through InvestingPro’s detailed research reports.
In other recent news, Neuronetics, a global leader in neuroscience, has embarked on several significant moves. The company recently launched an underwritten public offering of its common stock, with Canaccord Genuity LLC serving as the sole bookrunner for the transaction. The offering is subject to market and other conditions.
Neuronetics also reported a rise in revenue for the fourth quarter and the full year of 2024. The company announced revenues of $22.1 million for the fourth quarter and $74.5 million for the year. Post-acquisition adjustments after the recent acquisition of Greenbrook TMS revealed a pro forma consolidated revenue of $34.7 million for the fourth quarter and $129.8 million for the full year of 2024.
The company has identified over $22 million in annualized cost synergies, with more than 90% already implemented. Looking ahead to fiscal year 2025, Neuronetics expects a revenue range of $145.0 million to $155.0 million, which would represent a 12% to 19% increase on a pro forma basis. The company also aims to achieve cash flow breakeven by the third quarter of 2025. These are recent developments that investors should be aware of.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.